The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented has been only approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.
Clinical posters and presentations of the ESC Heart Failure 2022 Congress
Please see below to download PDFs and view videos of the presentations of the posters at the ESC Heart Failure 2022. Videos and posters will be available to view following presentation at the congress.
Some of the links to view the presentations or posters will link to the official ESC Heart Failure 2022 congress website. You may need to be a registered delegate and logged in the respective platform to view the content.
Finerenone
Monday 23 May, 2022 | 16:38 - 16:50 CEST
FIDELITY: Effect of Finerenone by LVH subgroup
Session: Late-Breaking Trials – Pharmacological treatment II Presenter: Gerasimos Filippatos
MA-M_FIN-ALL-0873-1